Clinical Trials
2 trialsNCT04781192 2026-01-23
The Purpose of This Trial is to Determine if Regorafenib Plus Durvalumab (MEDI4736) is Safe and Effective in Treatment of Chemo Refractory Advanced Biliary Tract Cancers
University of Kansas Medical Center
Phase 1/2 Active not recruiting
NCT05653180 2023-04-03
IBI310 in Combination With Sintilimab in Patients With Advanced Biliary Tract Cancer
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1/2 Unknown